The use of ketamine is considered “on-label” when it is used for medical purposes that the FDA has approved it for. When it is used for other conditions that are not covered by the FDA designation, then the use is considered “off-label”.
In early 2019, an esketamine nasal spray was approved by the FDA for adults with treatment-resistant depression. Its FDA-approved uses were later expanded to include patients suffering from acute suicidal ideation. But what is esketamine, and how is it different from regular ketamine?